Sean Ainsworth
Director/Board Member at OCUPHIRE PHARMA, INC.
Net worth: 148 441 $ as of 31/05/2024
Sean Ainsworth active positions
| Companies | Position | Start | End |
|---|---|---|---|
| OCUPHIRE PHARMA, INC. | Director/Board Member | 01/04/2018 | - |
| Independent Dir/Board Member | 01/04/2018 | - | |
RetroSense Therapeutics LLC
 RetroSense Therapeutics LLC Medical SpecialtiesHealth Technology RetroSense Therapeutics LLC provides biotechnology services. It offers gene therapies to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. The company was founded by Sean Ainsworth in 2009 and is headquartered in Ann Arbor, MI. | Chief Executive Officer | 01/01/2009 | - |
| Chairman | 01/01/2009 | - | |
| Founder | 01/01/2009 | - | |
Immusoft Corp.
 Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Chief Executive Officer | 05/01/2018 | - |
| Chairman | 05/01/2018 | - | |
Ray Therapeutics, Inc.
 Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Chairman | 01/01/2021 | - |
| Founder | 01/01/2021 | - |
Career history of Sean Ainsworth
Former positions of Sean Ainsworth
| Companies | Position | Start | End |
|---|---|---|---|
| Ainsworth Bioconsulting LLC | Founder | 01/01/2004 | 01/06/2012 |
| Corporate Officer/Principal | 01/01/2004 | 01/06/2012 | |
Compendia Bioscience, Inc.
 Compendia Bioscience, Inc. Information Technology ServicesTechnology Services Compendia Bioscience, Inc. provides information solutions for oncology drug discovery. The company was founded by Daniel D. Rhodes and Arul Chinnaiyan in February 2006 and is headquartered in Canton, MI. | Founder | 01/01/2006 | - |
| Genevivo LLC | Chief Executive Officer | - | - |
Training of Sean Ainsworth
| University of California San Diego | Undergraduate Degree |
| Washington University in St. Louis | Masters Business Admin |
Statistics
International
| United States | 9 |
| 2 |
Operational
| Founder | 4 |
| Chief Executive Officer | 3 |
| Chairman | 3 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 7 |
|---|---|
RetroSense Therapeutics LLC
RetroSense Therapeutics LLC Medical SpecialtiesHealth Technology RetroSense Therapeutics LLC provides biotechnology services. It offers gene therapies to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. The company was founded by Sean Ainsworth in 2009 and is headquartered in Ann Arbor, MI. | Health Technology |
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Health Services |
| Ocuphire Pharma, Inc. | |
| Ainsworth Bioconsulting LLC | |
| Genevivo LLC | |
Compendia Bioscience, Inc.
Compendia Bioscience, Inc. Information Technology ServicesTechnology Services Compendia Bioscience, Inc. provides information solutions for oncology drug discovery. The company was founded by Daniel D. Rhodes and Arul Chinnaiyan in February 2006 and is headquartered in Canton, MI. | Technology Services |
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Sean Ainsworth
- Experience
